Validation of Chlamydia Diagnostic Codes in TriNetX US EHR Data
Chlamydia Diagnostic Code Validation Using TriNetX EHR Data
Study Overview
This study is a pharmacoepidemiologic method study based on the secondary use of pre-existing data that examines whether TriNetX, a global health research network encompassing a worldwide electronic health record (EHR), database in the US is an appropriate real-world data (RWD) source for conducting chlamydia-related research to support the chlamydia trachomatis (CT) messenger Ribonucleic acid (mRNA) vaccine program.
There are two primary objectives for this study:
- To determine the validity of ICD, Tenth Revision, Clinical Modification (ICD-10-CM) diagnostic codes to identify patients with chlamydial infections using TriNetX EHR data in the US
- To describe screening or diagnostic testing and treatment patterns in patients with chlamydia using TriNetX EHR data in the US
There are also two secondary objectives for this study:
- To explore the feasibility of developing a modified algorithm for identifying patients with chlamydia applicable for Merative MarketScan Commercial Claims and Encounters (CCAE) database based on the findings from the primary objectives
- To compare patient characteristics, use of screening or diagnostic testing, and treatment patterns among patients with chlamydia between TriNetX EHR data and the MarketScan CCAE data in the US
Eligibility Criteria
You may be eligible for this study if you meet the following criteria:
- Conditions: Chlamydial Infections
-
Age: 14 years - 44 years
-
Gender: All
Inclusion Criteria for Primary Objectives:
- Patients with an ICD-10-CM diagnosis of chlamydia documented in their EHR OR patients with a nucleic acid amplification test (NAAT) result for chlamydia (either positive or negative) during the study period. The index date is the date of the first-recorded diagnosis code, or the date of the first-recorded NAAT result when no diagnosis code for chlamydia exists.
- Patients with at least one visit within 30 days both before and after their index date.
Exclusion Criteria for Primary Objectives:
- Patients with no documented ICD-10-CM diagnosis for chlamydia who possessed unknown laboratory test results for chlamydia during the study period (removed from ICD validation assessment in primary analysis).
- Patients with an ICD-10-CM diagnosis without a corresponding laboratory test (removed from ICD validation assessment in primary analysis).
Note: The above information is not intended to contain all considerations relevant to a potential participation in a clinical trial.
This study investigates chlamydia. It uses existing electronic health records (EHR) data from TriNetX, a global health research network, to see if it is a good source for chlamydia-related research.
The study evaluates how well certain diagnostic codes identify chlamydia infections and looks at testing and treatment patterns. It also explores ways to improve patient identification using different data sources.
- Who can participate: Adults with a documented ICD-10-CM diagnosis of chlamydia or a nucleic acid amplification test result for chlamydia are eligible. Participants must have had at least one visit within 30 days of their diagnosis date.
- Study details: Participants will have their medical records reviewed to check the accuracy of chlamydia diagnostic codes. Some may be compared with another database to see differences in testing and treatment patterns. A placebo is not used in this study.
Find a study site near you
,
Send a message
Enter your contact details to connect with study team
Primary Contact
Please choose between Voice or SMS based delivery of verification code
or